loss, or other non-specifi c symptoms (11, 12, 14) . Th e pancreatic gland may show focal or diff use swelling, and the pancreatic duct may show diff use or segmental narrowing on imaging (11, 15, 16) . Th e unique histological pattern observed in AIP has been described as lymphoplasmacytic sclerosis, which involves a duct-centric lymphoplasmacytic infi ltrate, storiform fi brosis concentrated around ducts and veins, and obliterative phlebitis -an infi ltrate that preferentially aff ects venules (12) . Th e presence of extrapancreatic manifestations is seen in approximately 40 -50 % of cases, which may precede the onset of AIP (1, 12, 17) . As described initially, three major sets of diagnostic criteria for AIP have been proposed (12, 18, 19) . However, it is increasingly recognized that many patients with suspected or proven AIP may not fulfi ll the established criteria (20) .
Apart from the Mayo Clinic (12) , reports on AIP from the United States have been limited to case reports (21 -23) . Th e aim of our study was to systematically review the evaluation and management in a large series of patients with AIP over a 10-year period at a tertiary care center in Pittsburgh (PA).
METHODS
Using the search terms, " autoimmune pancreatitis, " " lymphoplasmacytic sclerosing pancreatitis, " and " idiopathic rapidly progressive cholangitis, " we identifi ed 29 patients with AIP in our medical records database who were evaluated in the Pancreatobiliary Clinic of the Digestive Disorders Center at the University of Pittsburgh Medical Center between 1998 and 2007. Th ree of these 29 patients, who had other malignancies (gastric cancer diagnosed during the evaluation of biliary strictures (IgG4 positive on biopsy) in one patient, steroid-responsive biliary strictures in parallel with the recurrence of gastric adenocarcinoma in one, and pancreatic adenocarcinoma diagnosed in one steroid-unresponsive patient who was initially diagnosed as AIP on pancreatic biopsy) were excluded from the study. Medical records of the remaining 26 patients were reviewed to obtain information on demographics, clinical presentation, laboratory data, radiological and histological features, response to treatment, and relapse on follow-up. We evaluated whether a patient fulfi lled any of the three commonly used diagnostic criteria for AIP (Mayo Clinic ' s HISORt criteria, the Japanese Pancreas Society criteria, and Korean diagnostic criteria) (12, 18, 19) . Th e protocol was approved by the University of Pittsburgh Medical Center ' s Quality Improvement Committee.
Serum IgG4 levels were measured in 18 of 26 (69 % ) patients using automated nephelometry (IMMAGE, Beckman Coulter ' s immunochemistry systems). Elevated serum IgG4 level was denoted by levels > 140 mg / dl. Levels of > 280 mg / dl, which have recently been suggested to be highly specifi c for AIP, were noted (10) .
Eight out of the ten pancreatic histology specimens, obtained during the management of these patients, were available for a microscopic review. Th ese included six resection specimens, one exploratory wedge biopsy, and one endoscopic ultrasound (EUS)-guided trucut biopsy. One exploratory wedge biopsy and one computed tomography (CT)-guided pancreatic core biopsy were unavailable for review. Nine of the ten extrapancreatic histology specimens obtained during the management of these patients, were available for a microscopic review. Th ese included fi ve bile duct biopsies, one submandibular resection specimen, two ampullary biopsies, and one thyroid resection specimen. One submandibular resection was unavailable for review. All available specimens were reviewed by an expert pathologist (A.K.). Findings from the histology reports for the three specimens unavailable for review were noted.
Histological features used to support the diagnosis of AIP were similar to the study published from the Mayo clinic (12) . Th ese included the presence of a fi bro-infl ammatory process that was duct centric and contained numerous lymphocytes and plasma cells with variable neutrophils, obliterative venulitis, storiform fi brosis, and the presence of > 10 IgG4-positive plasma cells per high power fi eld (12) . Histological features used to support the diagnosis of extrapancreatic involvement included lymphoplasmacytic infi ltration, accompanying fi brosis, and the presence of > 10 IgG4-positive plasma cells per high power fi eld (4, 9, 12) . IgG4 immunohistochemical staining was performed on all available pancreatic and extrapancreatic histological specimens using monoclonal anti-human IgG4 antibody (Zymed, San Francisco, CA) using a standard technique in a formalin-fi xed paraffi n-embedded tissue.
All pre-and post-treatment imaging studies were systematically reviewed. Th ese included CT scans (in all 26 patients), Endoscopic Retrograde Cholangiograms (13 of 18), Endoscopic Retrograde Pancreatogram (13 of 14), magnetic resonance imaging (5 of 5), and positron emission tomogram (1 of 1) scans. EUS was successfully completed in 20 of 22 patients in whom it was attempted, and details of all studies were available for review.
A pancreatic mass was defi ned as the focal enlargement of the pancreas with a diff erent density compared with that of the surrounding tissue. Pancreatic enlargement was defi ned as the enlargement of the pancreas in the absence of a discrete mass. Biliary strictures were defi ned as distal (intrapancreatic) or proximal (extrapancreatic common bile duct (CBD), hilar, or intrahepatic). Isolated intrapancreatic stricturing was considered as a part of AIP, whereas proximal (extrapancreatic CBD, hilar, or intrahepatic) strictures were considered as extrapancreatic manifestations.
Th e presence of extrapancreatic organ involvement, such as extrapancreatic biliary strictures, retroperitoneal fi brosis, sialadenitis, and sclerosing mesenteritis was noted. Th e presence of other extrapancreatic fi ndings (e.g., vascular complications, splenic infarction, liver mass, enlarged lymph nodes, etc.) was recorded. In patients with diabetes mellitus, the timing of initial glucose intolerance and its relationship to the diagnosis of AIP was noted.
Information on the type of treatment (surgical or medical) was noted. In patients who received medical treatment, indication, dosage, duration, and regimen of immunosuppressive therapy used was recorded. Response to therapy was defi ned as complete when symptomatic improvement and complete resolution of imaging abnormalities was present. In patients with a pancreatic mass, a complete resolution of imaging
PANCREAS
Evaluation and Management of AIP abnormalities was considered when the pancreas appeared normal or atrophic post treatment. In patients with biliary and / or pancreatic duct strictures, a complete resolution was defi ned by a return to normal caliber. An incomplete response to therapy was defi ned by partial symptomatic improvement and / or incomplete resolution of mass lesions or biliary strictures. In these cases, prolonged treatment with corticosteroids ( > 12 weeks) in conjunction with steroid-sparing agents (azathioprine) was attempted. In one patient, treatment was initiated with methotrexate. Of the 16 patients who fulfi lled the HISORt criteria, the diagnosis of AIP was established on pancreatic histology in 7 patients (total or partial pancreatic resection in 6 and CT-guided biopsy in 1), characteristic radiographic and serologic features in 8 patients, and by a combination of extrapancreatic involvement, serology, and response to treatment in 1 patient. In the 10 patients who did not fulfi ll the HISORt criteria, the diagnosis of AIP was established by a combination of characteristic imaging abnormality (pancreatic plus biliary in 7 and isolated pancreatic in 3 patients), elevated antinuclear antibody (ANA) ( n = 3), resolution of radiographic abnormalities with immunosuppressive therapy, and exclusion of alternative diagnoses, such as pancreatic and biliary cancer. Data on demographics, clinical presentation, laboratory data, radiological fi ndings, histological features, response to treatment, and relapse on follow-up in patients meeting the HISORt criteria ( n = 16), and those not meeting the HISORt criteria for AIP ( n = 10) (12) are presented in Tables 1 and 2 , respectively.
RESULTS

Between
Clinical presentation
Th e median age of patients at presentation was 62.5 years (range: 23 -86). Two-thirds of the patients were ≥ 50 years of age, two-thirds were men, and all but three (88 % ) patients were Caucasians. Th e most common presenting symptoms included new-onset abdominal pain in 17 (65 % ), obstructive jaundice in 16 (62 % ), weight loss in 11 (42 % ), and steatorrhea in 5 (19 % ) patients. Pain was mild in 16 of the 17 patients with new-onset abdominal pain that did not need narcotics for pain control. Two additional patients were on narcotics for chronic abdominal pain of unclear etiology, which was unrelated to the diagnosis of AIP. Overall, 6 of 26 patients (23 % ) had diabetes mellitus at the time of evaluation. Four of these patients had developed diabetes within 2 years preceding the diagnosis of AIP. Th e other two patients had long-standing diabetes but reported worsening of glycemic control in the months preceding the diagnosis of AIP. Glycemic control improved in fi ve out of six patients with diabetes aft er treatment with corticosteroids. One patient was lost to follow-up.
Serology
An increase in serum IgG4 level to > 140 and > 280 mg / dl was observed in 8 (44.4 % ) and 5 (27.8 % ) of the 18 patients, respectively, in whom it was measured. Interestingly, one patient with normal IgG4 levels at presentation had increased serum IgG4 during recurrence of the disease. Antinuclear antibody titer was increased to ≥ 1:80 in 10 of 20 (50 % ) cases in whom it was measured. Cancer associated antigen 19-9 (CA 19-9) was measured in 15 patients and was increased ( > 38 U / ml) in 4 (27 % ) patients.
Imaging studies
On pre-treatment CT scans ( n = 26), 15 patients had a pancreatic mass (head in 8, tail in 5, body in 1, and multifocal in 1), 4 had diff use pancreatic enlargement, 3 had localized prominence of the pancreas without a distinct mass, and 4 patients had a normal-appearing pancreas. Th e fi ndings on ERCP (endoscopic retrograde cholangiopancreatography) showed pancreatic duct stricture in 13 patients (diff use in 7, focal in 6), distal (intrapancreatic) CBD stricture in 8, proximal CBD stricture in 3, hilar stricture in 5, and intrahepatic biliary stricture in 4 patients. Th ree of the patients with extensive hilar stricturing were initially diagnosed as cholangiocarcinoma. EUS fi ndings in the 20 patients with a completed examination included a hypoechoic pancreatic mass in 13, diff use hypoechoic and / or heterogeneous pancreatic parenchymal changes in 13, the main pancreatic duct stricture with upstream dilatation in 4, and features of chronic pancreatitis in 2 patients. EUS fi ndings in the four patients with a normal-appearing pancreas on CT scan included a hypoechoic mass in the head of the pancreas in one, hypoechoic changes and pancreatic duct narrowing in the tail of the pancreas in one, diff use hypoechoic changes in the head and body of the pancreas in one, and pancreatic duct narrowing with hypoechoic changes in the head of the pancreas in one. EUS-guided fi ne needle aspiration cytology of the pancreas was performed in 19 patients. EUS-guided core biopsy was performed in one patient showing features of LPSP, but the IgG4 staining was negative.
At diagnosis, 6 of the 26 (23 % ) patients were found to have involvement of major peri-pancreatic vasculature, including encasement and thrombosis of splenic vessels, splenic infarction secondary to splenic vascular involvement, and occlusion of the confl uence between superior mesenteric, portal, and splenic veins ( Table 3 and Figure 1 ). Hypercoagulable workup in all of these patients was negative. Vascular fi ndings were more common in patients who had a mass in the pancreatic tail or diff use pancreatic enlargement. Th e clinical course of one patient with splenic vein thrombosis was complicated by hematemesis secondary to gastric variceal bleeding that necessitated the placement of vascular coils to control bleeding ( Figure 1a ). In another patient, portal hypertensive gastropathy was observed during ERCP. None of these patients were treated with anticoagulants.
Histology and cytology
Of the 10 patients who underwent pancreatic histology, histological examination and IgG4 staining in 7 patients supported the diagnosis of AIP. One patient whose biopsy specimens did not fulfi ll all histological criteria for AIP had received prednisone for 4 weeks before obtaining biopsy specimens. One patient was diagnosed as chronic pancreatitis at an outside facility and his specimen was unavailable for review. Histological examination of extrapancreatic specimens supported the diagnosis of chronic sclerosing sialadenitis with positive IgG4 staining in two patients. Of the remaining eight extrapancreatic histology specimens (fi ve bile duct, two ampullary, and one thyroid), four were inadequate and four were inconclusive ( Tables 1 and 2 ). An ampullary biopsy obtained in two patients was inconclusive.
EUS-guided fi ne needle aspiration was performed on 19 patients. Th ere was no evidence of malignancy in 18 patients; epithelial features suspicious for malignancy were noted in one patient, which led to a pancreatic resection. Four of our 19 patients had either lymphocytes or stromal fragments in the absence of malignancy (but not both), and these subtle features were insuffi cient to render a diagnosis of AIP.
Extrapancreatic manifestations
Extrapancreatic involvement was observed in nine (35 % ) patients at presentation. Th is included biliary strictures (proximal CBD, hilar, or intrahepatic) in seven patients, and biliary strictures plus chronic sclerosing sialadenitis in two patients. Biliary dilatation and stenting was performed in all of these patients at initial presentation, and stents were removed aft er the resolution of strictures with immunosuppressive therapy. During follow-up, some patients required repeated dilatation and stenting. One of the patients with biliary strictures also had histologically confi rmed Riedel ' s thyroiditis and sclerosing mesenteritis. Two patients had submandibular gland swelling and two others had retroperitoneal fi brosis, but a histological evaluation was not performed in them.
Abnormally enlarged lymph nodes (>1 cm in long axis) in the upper abdomen (peri-pancreatic, porta hepatis, celiac, aortocaval) were seen on imaging studies in nine patients. ( Figure 2 ) was observed in 15 (79 % ) and incomplete response in 4 (21 % ) patients. Among the 15 patients with a complete response, 9 had a recurrence within 8 -12 weeks of steroid withdrawal presenting as recurrent biliary strictures in 4, recurrent pancreatic swelling in 3, and as recurrent stricturing of the main pancreatic duct in 2 patients. Recurrences were treated with corticosteroids during the acute fl are-up and azathioprine was added for longterm immunosuppression. All nine patients responded and are being maintained on long-term azathioprine. Four of the 15 patients who responded completely with the initial therapy had no evidence of recurrence aft er steroid withdrawal during a follow-up of 5, 5, 5, and 6 months, respectively. One of the complete responders was lost to follow-up and one was being tapered off steroids at the end of the study period. Among the four patients with incomplete response to steroids, two had persistent pancreatic enlargement (complicated in one by the development of a cyst in the body and the tail), whereas two patients had partial resolution of biliary strictures. Of these four patients, three (including both patients with resistant biliary strictures) eventually responded to a combination of prednisone and azathioprine for 8, 4, and 4 months, respectively, followed by azathioprine alone. Attempts for withdrawing azathioprine in the two patients with biliary strictures were EUS-guided fi ne needle aspiration cytology was performed in fi ve of these patients and was negative for malignancy.
Treatment and follow-up
Six patients underwent partial or complete pancreatectomy for suspected pancreatic adenocarcinoma. One of these six patients had been treated empirically with prednisone for 4 weeks with no clinical and radiological improvement and underwent pancreatic tail resection. Th is patient and three other patients were followed-up aft er surgery for 6, 8, 10, and 36 months, respectively, without recurrence of disease. Th e remaining two patients were lost to follow-up.
One patient seen in the initial study period was treated with methotrexate. He responded completely within 6 weeks of initiating the therapy and remission was maintained with methotrexate 15 mg orally every week. Eight months later, he developed a recurrent biliary stricture treated with corticosteroid, balloon dilatation, and stenting, and azathioprine was added for long-term immunosuppression. A second recurrence was documented 5 years later, which was treated with corticosteroid, balloon dilatation, and stenting. Th is patient was on chronic immunosuppression with azathioprine at the end of the study period.
Th e remaining 19 patients received corticosteroids as the initial treatment. Th e usual regimen was oral prednisone unsuccessful because of recurrent stricturing. Th e remaining one patient with incomplete response to steroids was started on azathioprine a few weeks before the end of the study period.
A subset analysis of treatment response in nine patients with extrapancreatic biliary strictures showed recurrence in 78 % (7 / 9) aft er the withdrawal of immunosuppressive therapy. Four of the six patients who had achieved complete remission with initial prednisone therapy relapsed within 6 -8 weeks of treatment withdrawal. Two patients with incomplete response to steroids, who had achieved complete remission with prolonged prednisone and azathioprine therapy, experienced relapse within 6 -8 weeks of treatment withdrawal. One patient who was initially managed with methotrexate experienced a relapse while on treatment. Recurrences in all of these patients were similar to recurrent hilar and / or intrahepatic biliary strictures. Aft er the fi rst relapse, all patients were treated with prednisone and azathioprine, and long-term remission was achieved in six patients (median follow-up: 6, range: 5 -84 months). Th ree patients experienced more than one relapse, requiring a high dose of corticosteroids during disease fl ares. One patient developed atrophy of the left lobe of the liver secondary to recurrent stricturing of intrahepatic biliary ducts.
One patient with pancreatic tail mass who underwent pancreatic tail resection and splenectomy had no evidence of splenic vascular compromise on repeat studies at 1 year. Five other patients who had vascular complications received immunosuppression for AIP. During follow-up, chronic splenic occlusion was observed in three of these fi ve patients at 6, 8, and 14 months, respectively; stable splenic infarcts were seen in two and persistent gastric varices were observed in two patients.
DISCUSSION
Our report is the second major series on AIP patients from the United States. We confi rm several of the fi ndings on clinical presentation, imaging, and treatment response reported in previous studies on AIP (1,12 -14,19,24) . Th e lack of sensitivity of the currently established clinical criteria for diagnosis observed by us indicates that our knowledge of the complete spectrum of this disease is still evolving. Our study highlights the presence of vascular complications in a subset of AIP patients.
At presentation, none of the three commonly used diagnostic criteria (HISORt, the Japanese Pancreas Society, and Korean) were fulfi lled in 15 % of the patients (12, 19) . A lower sensitivity can be explained by several factors. Serum IgG4 was not measured in 8 / 26 patients. Four of these eight patients were evaluated before 2002 when the association between IgG4 and LPSP was not well known (13) . Th ese four patients had unexplained pancreatic disease (pancreatic mass plus biliary strictures) with a negative workup for known etiologies, including cancer. A complete resolution of pancreatic and / or extrapancreatic manifestations with immunosuppressive therapy (12 weeks or long term) was noted in all four patients. An increased serum IgG4 would have satisfi ed the HISORt B criteria in these patients.
Another four patients seen aft er 2002 underwent pancreatic resections for presumed pancreatic cancer without determination of IgG4 (all had LPSP and positive IgG4 staining). Of the two patients whose pancreatic biopsies did not fulfi ll all histological features of AIP, one had received an empirical steroid trial aft er pancreatic cancer was ruled out by EUS. Eight extrapancreatic histological specimens were either inconclusive or inadequate for evaluation. ERCP was not performed in all patients to delineate the presence of the irregular, non-dilated pancreatic duct, and fi nally, an excellent response to treatment with steroids was observed. None of the patients were diagnosed with pancreas or biliary cancer (the most common diff erential diagnosis). Th e clinical course and response to treatment indicates accuracy of AIP diagnosis in a majority of our patients. Pursuing additional workup (biopsies, ERCP, surgery) to enable fulfi llment of the established criteria could have resulted in a higher sensitivity.
Several of the fi ndings on clinical presentation (age, gender, prevalence of jaundice, diabetes, steatorrhea, and prevalence of extrapancreatic manifestations) in our series were similar to those reported from the United States, Japan, and other centers (11 -14) . Although the proportion of patients reporting abdominal pain in our series was higher than previously reported (12, 14) , it is important to note that the pain was mild in most patients and did not require narcotics for pain control. Two patients had chronic abdominal pain of unclear etiology and were on narcotics. Th ey did not report a history of chronic alcoholism, and their imaging studies did not show features of chronic pancreatitis. Abdominal pain in both patients persisted despite resolution of pancreatic / extrapancreatic manifestations with steroids.
Serum IgG4 measurements are now performed routinely in patients with suspected AIP. Th e proportion of patients who had an increase in IgG4 (>140 mg / dl in 44 % and >280 mg / dl in 27.8 % ) was lower than reported by Chari and colleagues (10) (>280 mg / dl in 53 % ). Although the exact reason for this diff erence is unclear, it emphasizes that a lack of IgG4 increase does not exclude the presence of AIP. At the same time, it is important to recognize that mild increases are oft en seen in patients with pancreatic cancer (10, 25) , which is the most important diff erential diagnosis of AIP.
EUS-guided fi ne needle aspiration was performed on 19 patients primarily to evaluate for malignancy, which is the most important diff erential diagnosis in patients with suspected AIP. In 18 out of 19 patients, a diagnosis of pancreatic cancer could be ruled out with confi dence. In one patient, epithelial features suspicious of malignancy were noted leading to pancreatic resection. A recent study reported that clinical and radiological fi ndings in conjunction with stromal fragments containing a lymphoid infi ltrate on fi ne needle aspiration cytology could support a diagnosis of AIP and exclude carcinoma (26, 27) . Four of our 19 patients had either lymphocytes or stromal fragments in the absence of malignancy (but not both), and these subtle features were insuffi cient to render a diagnosis of AIP. Recent reports have indicated that a core specimen obtained by trucut biopsy during EUS can be used to histologically PANCREAS Evaluation and Management of AIP vascular fi ndings and complications involving the peri-pancreatic vasculature occur in a subset of AIP patients.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
3 Autoimmune pancreatitis (AIP) is a treatable form of pancreatitis that is increasingly recognized.
3 AIP is part of a systemic fi bro-infl ammatory syndrome complex known as immunoglobulin-4 (IgG4)-related systemic disease. diagnose AIP (26, 28) . However, this procedure can be performed only at expert centers by endosonographers with considerable experience. As the risk associated with EUS-guided fi ne needle aspiration is low, we believe that the primary role of fi ne needle aspiration during the evaluation of a patient with suspected AIP will be to rule out malignancy, rather than to rule in a diagnosis of AIP.
An important observation in our study was the presence of peri-pancreatic vascular complications in 23 % (6 / 26) of the patients. Th ese fi ndings varied from compression of vasculature to frank encasement and thrombosis of splenic, mesenteric vessels, and splenic infarction secondary to vascular compromise. Vascular complications were found to be closely related to the site of pancreatic infl ammation and mass formation. Although the exact cause of this fi nding is unclear, we speculate that pancreatic and peri-pancreatic infl ammation could have resulted in stasis and infl ammation of the vascular wall predisposing the vessel to develop thrombosis.
Similar to previous reports, an excellent response was seen in an initial course of steroids (7,29 -31) . However, recurrences were common and necessitated the concomitant use of azathioprine to maintain remission. Recurrences were seen more frequently in patients who had extrapancreatic biliary strictures. IgG4-associated cholangitis is a newly described entity representing biliary manifestations of the IgG4-related systemic disease (2, 32, 33) . It is defi ned as biliary strictures that respond to or improve with steroid therapy (2, 32, 33) and can oft en be confused with primary sclerosing cholangitis (2,32 -36) . Biliary strictures in these patients can be isolated or involve non-contiguous areas of bile duct. Nine patients in our series had evidence of isolated ( n = 6) or multi-focal biliary ( n = 3) stricturing proximal to the intrapancreatic portion of the bile duct that responded to steroid therapy. Although histology specimens obtained were not helpful in establishing diagnosis (inadequate in fi ve and inconclusive in one), other features (dramatic response to steroids, concomitant presence of steroid responsive pancreatic mass, elevated IgG4 in three, ANA in three) strongly suggest the diagnosis of IAC in these patients. Th e higher mean age (63 years) of patients with extrapancreatic biliary strictures in our study compared with the typical age for primary sclerosing cholangitis was also similar to previous observations (2,32 -36) . None of these patients were previously diagnosed with primary sclerosing cholangitis or infl ammatory bowel disease. Our fi ndings are also consistent with recent reports of a high relapse rate aft er initial steroid treatment among patients with proximal biliary strictures (2) . We believe that in patients with proximal strictures, it may be reasonable to start steroid-sparing immunosuppressant with the initial steroid therapy.
In summary, we report the second largest series on AIP patients from the United States. We confi rm several fi ndings on clinical presentation and management of these patients. Th e diff erences in our series from previous reports highlight the evolution of our knowledge of this disease. We report that
